fet5 Antibody

What are FET family proteins and which antibodies are available for their detection?

The FET family of RNA binding proteins includes three major members: TATA-binding protein-associated factor 2N (TAF15), Fused in Sarcoma (FUS), and RNA binding protein EWS (EWS) . These proteins play critical roles in transcriptional regulation and RNA metabolism . Several commercial antibodies are available for detection of these proteins, with varying specificity and applications:

• For TAF15: Multiple validated antibodies including TAF15-IHC-00094-1, TAF15-309A, and TAF15-308A (Bethyl)

• For EWS: Validated antibodies include EWS-G5 (Santa Cruz), EWS-IHC-00086 (Bethyl), EWS-3319-1 and EWS-3320-1 (Epitomics)

• For FUS: Multiple options including polyclonal anti-FUS HPA008784 (Sigma-Aldrich), FUS-302A (Bethyl), and monoclonal anti-FUS (ProteintechGroup)

When selecting an antibody, consider its validated applications (Western blot, immunofluorescence, immunohistochemistry), species reactivity, and previous validation studies.

How do I evaluate antibody specificity for FET proteins given their sequence homology?

Due to the high homology between FET family members, cross-reactivity is a significant concern. Proper validation should include:

• Testing antibodies on knockout or knockdown models of the target protein

• Immunoblot analysis to confirm the antibody recognizes a band of the expected molecular weight

• Verification of specificity by testing against other FET family members

For example, researchers have excluded potential cross-reactivity of TAF15 and EWS antibodies with FUS by immunoblot analysis . Always test new antibodies against cell lines with known expression levels of all three FET proteins to ensure specificity.

What are the optimal protocols for detecting FET proteins in tissue sections?

For detecting FET proteins in formalin-fixed paraffin-embedded (FFPE) tissue sections:

• Antigen retrieval: Heat-mediated antigen retrieval in citrate buffer (pH 6.0) is generally effective for FET protein epitopes

• Antibody selection: Use antibodies validated for immunohistochemistry (IHC) applications

  • For TAF15: TAF15-IHC-00094-1 (Bethyl) has been validated for IHC

  • For EWS: EWS-G5 (Santa Cruz) has shown good results in tissue sections

• Detection method: Both chromogenic and fluorescent detection methods work well

• Controls: Include both positive and negative controls, particularly tissues known to express or lack expression of the target protein

For co-localization studies, double-label immunofluorescence can be performed using appropriate combinations of antibodies, such as FUS with TAF15 or EWS, followed by detection with fluorophore-conjugated secondary antibodies (e.g., Alexa Fluor 594 and Alexa Fluor 488) .

What are the best practices for using FET antibodies in Western blot applications?

For optimal Western blot results when detecting FET proteins:

• Sample preparation: Use RIPA buffer with protease inhibitors for extraction

• Protein loading: 20-40 μg of total protein per lane is typically sufficient

• Transfer conditions: Semi-dry transfer at 15V for 30 minutes often works well for FET proteins

• Blocking: 5% non-fat dry milk in TBST for 1 hour at room temperature

• Antibody dilutions:

  • For TAF15: TAF15-308A at 1:1000 to 1:10,000 dilution

  • For EWS: EWS-G5 at 1:1000 dilution

  • For FUS: HPA008784 at 1:2000 or FUS-302A at 1:10,000

• Controls: Include appropriate positive and negative controls

How can I optimize immunoprecipitation protocols for studying FET protein interactions?

For successful immunoprecipitation (IP) of FET proteins:

• Lysis buffer selection: Use mild lysis buffers (e.g., 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40) to preserve protein-protein interactions

• Antibody selection: Choose antibodies validated for IP applications

• Pre-clearing: Pre-clear lysates with protein A/G beads to reduce non-specific binding

• Antibody incubation: Incubate antibodies with lysates overnight at 4°C

• Washing conditions: Use stringent washing to remove non-specific interactions

• Elution methods: Choose between denaturing (SDS) or non-denaturing (peptide competition) elution based on downstream applications

Cross-linking the antibody to beads can reduce antibody contamination in eluates for mass spectrometry applications.

How do I design experiments to study FET proteins in neurodegenerative disease models?

When investigating FET proteins in neurodegenerative disease contexts:

• Subcellular localization: Examine nuclear versus cytoplasmic distribution using immunofluorescence with antibodies validated for this application

  • FUS-positive inclusions in amyotrophic lateral sclerosis (ALS) with FUS mutations are exclusively labeled for FUS

  • FUS-positive inclusions in frontotemporal lobar degeneration (FTLD) consistently co-label with TAF15 and variably with EWS

• Protein solubility: Analyze protein extracts fractionated into soluble and insoluble fractions

  • In FTLD with FUS pathology, all FET proteins show a relative shift toward insoluble protein fractions

• Co-localization studies: Use double-label immunofluorescence to assess co-localization with other disease markers

  • Consider combinations with α-internexin for neuronal intermediate filament inclusion disease

• Controls: Compare findings between disease and control tissues/cells using identical protocols

What are the considerations when using FET antibodies for targeted mass spectrometry applications?

When developing targeted mass spectrometry methods with FET antibodies:

• Antibody enrichment strategy: Choose between peptide immunoaffinity enrichment or protein immunoprecipitation followed by digestion

• Epitope interference: Consider whether the antibody epitope might be modified or obscured in the disease state

• Reference peptides: Select appropriate reference peptides that uniquely identify each FET protein

• Internal standards: Include isotopically labeled peptide standards for quantification

• Validation: Validate the method using spike-in experiments with recombinant proteins

For optimal results, follow established protocols for antibody-based targeted mass spectrometry as described for other proteins in the RAS network .

What are common pitfalls when using FET antibodies and how can they be avoided?

Common challenges when working with FET antibodies include:

• Cross-reactivity: Due to sequence homology between FET family members

  • Solution: Validate antibody specificity using knockout/knockdown models or comparative analysis with multiple antibodies

• Weak signal in IHC/IF: May result from epitope masking or fixation issues

  • Solution: Test different antigen retrieval methods and fixation protocols

• High background: Can obscure specific signals

  • Solution: Optimize blocking conditions and antibody concentrations; consider using alternative antibodies

• Inconsistent results: May reflect lot-to-lot variations

  • Solution: Record lot numbers and validate each new lot against previous ones

How can I validate FET antibodies for reproducible research?

To ensure reproducibility when using FET antibodies:

• Knockout validation: Test antibodies in knockout cell lines compared to isogenic parental controls

• Multimodal validation: Validate using multiple techniques (Western blot, IP, IF/IHC)

• Positive/negative controls: Include appropriate controls in every experiment

• Detailed methods reporting: Document complete antibody information (supplier, catalog number, lot, dilution)

• Antibody registry: Register antibodies in databases to support reproducibility

Following community consensus principles for antibody validation will significantly enhance result reproducibility .

How can FET antibodies be utilized in biosensor development?

While traditional antibody applications focus on protein detection in biological samples, emerging technologies incorporate antibodies into biosensor systems:

• FET-based biosensors: Field-effect transistor (FET) biosensors can be developed using antibodies as recognition elements

  • These sensors typically consist of a channel (e.g., reduced graphene oxide), electrodes, and a functionalized surface with immobilized antibodies

  • The binding of target molecules to antibodies alters the electronic properties of the channel, producing a measurable signal

• Design considerations:

  • Channel material selection (e.g., reduced graphene oxide)

  • Antibody immobilization strategy to preserve activity

  • Signal enhancement approaches (e.g., metal nanoparticle decoration)

  • Specificity validation against similar targets

• Performance optimization:

  • Metal nanoparticles (silver, copper) can enhance biosensing performance by increasing surface area and improving charge transfer

  • Semi-empirical modeling approaches can be used to predict and optimize sensor performance

What are emerging areas of research involving FET protein antibodies?

Future research with FET protein antibodies is likely to focus on:

• Post-translational modifications: Developing antibodies specific to different post-translational modifications of FET proteins

• Structural variations: Creating antibodies that can distinguish between different structural conformations, particularly in disease states

• High-throughput applications: Adapting antibodies for use in high-throughput screening platforms

• In vivo imaging: Developing methods for in vivo visualization of FET proteins using modified antibodies

• Therapeutic applications: Exploring the potential of antibodies in targeting FET proteins for therapeutic intervention in cancers and neurodegenerative diseases

Researchers should stay informed about new antibody development and validation studies to take advantage of emerging tools for FET protein research.